KR102601505B1 - 안과 질환의 치료 방법 - Google Patents

안과 질환의 치료 방법 Download PDF

Info

Publication number
KR102601505B1
KR102601505B1 KR1020237009057A KR20237009057A KR102601505B1 KR 102601505 B1 KR102601505 B1 KR 102601505B1 KR 1020237009057 A KR1020237009057 A KR 1020237009057A KR 20237009057 A KR20237009057 A KR 20237009057A KR 102601505 B1 KR102601505 B1 KR 102601505B1
Authority
KR
South Korea
Prior art keywords
nicotinic acetylcholine
receptor agonist
acetylcholine receptor
foregoing embodiments
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237009057A
Other languages
English (en)
Korean (ko)
Other versions
KR20230042144A (ko
Inventor
더글라스 마이클 주니어 애커만
제임스 로우딘
케네스 제이. 만델
Original Assignee
오이스터 포인트 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102601505(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오이스터 포인트 파마 인코포레이티드 filed Critical 오이스터 포인트 파마 인코포레이티드
Publication of KR20230042144A publication Critical patent/KR20230042144A/ko
Application granted granted Critical
Publication of KR102601505B1 publication Critical patent/KR102601505B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
KR1020237009057A 2014-10-20 2015-10-19 안과 질환의 치료 방법 Active KR102601505B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US62/066,280 2014-10-20
US201562100844P 2015-01-07 2015-01-07
US62/100,844 2015-01-07
KR1020177013534A KR102511955B1 (ko) 2014-10-20 2015-10-19 안과 질환의 치료 방법
PCT/US2015/056273 WO2016064759A1 (en) 2014-10-20 2015-10-19 Methods of treating ocular conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177013534A Division KR102511955B1 (ko) 2014-10-20 2015-10-19 안과 질환의 치료 방법

Publications (2)

Publication Number Publication Date
KR20230042144A KR20230042144A (ko) 2023-03-27
KR102601505B1 true KR102601505B1 (ko) 2023-11-14

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237009057A Active KR102601505B1 (ko) 2014-10-20 2015-10-19 안과 질환의 치료 방법
KR1020177013534A Active KR102511955B1 (ko) 2014-10-20 2015-10-19 안과 질환의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177013534A Active KR102511955B1 (ko) 2014-10-20 2015-10-19 안과 질환의 치료 방법

Country Status (21)

Country Link
US (14) US9532944B2 (https=)
EP (3) EP3848028B9 (https=)
JP (3) JP6873906B2 (https=)
KR (2) KR102601505B1 (https=)
CN (3) CN111956650B (https=)
AU (2) AU2015336216B2 (https=)
BR (2) BR112017008097B1 (https=)
CA (1) CA2965129C (https=)
DK (2) DK3848028T5 (https=)
EA (1) EA035335B1 (https=)
ES (2) ES2986830T3 (https=)
FI (1) FI3848028T3 (https=)
IL (3) IL251769B (https=)
MX (2) MX392383B (https=)
MY (1) MY186870A (https=)
PH (1) PH12017500602A1 (https=)
PL (1) PL3848028T3 (https=)
PT (2) PT3848028T (https=)
SG (2) SG11201703135XA (https=)
WO (1) WO2016064759A1 (https=)
ZA (1) ZA201703467B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3848028B9 (en) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
MX385698B (es) * 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
ES3039903T3 (en) * 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531168A (ja) * 2000-04-21 2003-10-21 インスパイアー ファーマシューティカルズ，インコーポレイティド ニコチン・アセチルコリン受容体アゴニストによるドライ・アイ疾患の治療方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
EP1461040B1 (en) 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
MX2007004495A (es) 2004-10-15 2007-05-10 Pfizer Prod Inc Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
AU2005304035B2 (en) * 2004-11-09 2010-07-22 Santen Sas Ophthalmic oil-in-water type emulsion with stable positive zeta potential
WO2006100075A2 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
CA2999420A1 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
HRP20110702T1 (hr) * 2007-02-02 2011-10-31 Pfizer Products Inc. Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora
CN103977003A (zh) * 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010028033A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010065443A1 (en) 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
BR112013032044A2 (pt) * 2011-06-30 2016-12-13 Toray Industries antiprurítico
ES2776996T3 (es) * 2011-10-20 2020-08-03 Novartis Ag Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7
EP2786142A4 (en) * 2011-11-30 2015-07-22 Diagnostear Ltd DIAGNOSIS OF THE DRY EYE
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
HUE034886T2 (hu) 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
NZ704579A (en) 2013-04-19 2018-10-26 Oculeve Inc Nasal stimulation devices and methods
EP3848028B9 (en) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
MX385698B (es) 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531168A (ja) * 2000-04-21 2003-10-21 インスパイアー ファーマシューティカルズ，インコーポレイティド ニコチン・アセチルコリン受容体アゴニストによるドライ・アイ疾患の治療方法

Also Published As

Publication number Publication date
AU2015336216B2 (en) 2020-05-21
US11903943B2 (en) 2024-02-20
IL251769A0 (en) 2017-06-29
IL293188B2 (en) 2025-06-01
IL293188A (en) 2022-07-01
BR112017008097B1 (pt) 2023-03-28
CN107106542B (zh) 2020-05-08
SG10202011669PA (en) 2020-12-30
DK3209295T4 (da) 2024-02-26
JP2023024574A (ja) 2023-02-16
JP7257371B2 (ja) 2023-04-13
CN107106542A (zh) 2017-08-29
KR102511955B1 (ko) 2023-03-22
EP3848028B9 (en) 2024-10-16
EA201790893A1 (ru) 2018-01-31
EA035335B1 (ru) 2020-05-28
US11911380B2 (en) 2024-02-27
US20160106744A1 (en) 2016-04-21
US10456396B2 (en) 2019-10-29
CN111956803A (zh) 2020-11-20
IL293188B1 (en) 2025-02-01
MX2022005888A (es) 2022-06-14
US9504645B2 (en) 2016-11-29
DK3848028T3 (da) 2024-08-26
EP3209295B2 (en) 2023-12-06
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
US20200246336A1 (en) 2020-08-06
KR20230042144A (ko) 2023-03-27
US11224598B2 (en) 2022-01-18
CA2965129C (en) 2024-03-12
EP3848028B1 (en) 2024-05-29
US9504644B2 (en) 2016-11-29
MX2017005064A (es) 2018-02-23
JP2017531044A (ja) 2017-10-19
WO2016064759A1 (en) 2016-04-28
US20230226052A1 (en) 2023-07-20
DK3848028T5 (da) 2025-01-20
US20250255865A1 (en) 2025-08-14
US20230226054A1 (en) 2023-07-20
AU2020213351A1 (en) 2020-08-27
US12576080B2 (en) 2026-03-17
IL251769B (en) 2022-06-01
US11903941B2 (en) 2024-02-20
JP2021038250A (ja) 2021-03-11
US20160106665A1 (en) 2016-04-21
BR112017008097A2 (pt) 2018-02-20
DK3209295T3 (da) 2021-03-01
ES2986830T3 (es) 2024-11-12
US9597284B2 (en) 2017-03-21
MX392383B (es) 2025-03-24
EP4413974A3 (en) 2024-10-09
US9532944B2 (en) 2017-01-03
ES2848977T3 (es) 2021-08-13
CN111956803B (zh) 2025-10-31
FI3848028T3 (fi) 2024-08-21
MY186870A (en) 2021-08-26
AU2020213351B2 (en) 2023-04-06
US20250235449A1 (en) 2025-07-24
ES2848977T5 (es) 2024-06-06
SG11201703135XA (en) 2017-05-30
CN111956650B (zh) 2024-06-04
AU2015336216A1 (en) 2017-06-08
PL3848028T3 (pl) 2024-11-18
EP3848028A1 (en) 2021-07-14
BR122022025737B1 (pt) 2023-12-26
PH12017500602A1 (en) 2017-09-04
US20170239244A1 (en) 2017-08-24
PT3209295T (pt) 2021-02-05
CA2965129A1 (en) 2016-04-28
IL318427A (en) 2025-03-01
JP7502404B2 (ja) 2024-06-18
US11903942B2 (en) 2024-02-20
EP3209295A1 (en) 2017-08-30
PT3848028T (pt) 2024-09-20
KR20170086040A (ko) 2017-07-25
EP3209295A4 (en) 2018-05-23
JP6873906B2 (ja) 2021-05-19
EP3209295B1 (en) 2020-12-09
EP4413974A2 (en) 2024-08-14
US20160106745A1 (en) 2016-04-21
US20230226053A1 (en) 2023-07-20
US20250275963A1 (en) 2025-09-04
CN111956650A (zh) 2020-11-20
US20240173318A1 (en) 2024-05-30
ZA201703467B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
JP7502404B2 (ja) 眼の病状の治療方法
HK40035962A (en) Methods of treating ocular conditions
HK40035961A (en) Methods of treating ocular conditions
HK40049315B (en) Methods of treating ocular conditions
HK40049315A (en) Methods of treating ocular conditions
HK40035961B (zh) 治疗眼部病状的方法
HK40035962B (zh) 治疗眼部病状的方法
HK1242208A1 (en) Methods of treating ocular conditions
HK1242208B (en) Methods of treating ocular conditions

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000